David Hildick Smith - What’s new: clinical data published and presented since last year
About this lecture
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Per Wester - NOACs; advances and limitations in real world
New oral anticoagulants or NOACs, with favorable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. There are still limitations associated. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for treatment. The focus on NOACs has shifted to the practical approach and management in real life.